Ohio State Navbar

Sign In

RSS Feed Regenerative Medicine News

Center for Regenerative Medicine and Cell-Based Therapies Welcomes Two New Recruits 


Brent D. Toto, MHA
Director, CRMCBT
Department of Surgery, The Ohio State University

Mr. Toto has extensive leadership experience in building teams and improving and expanding healthcare programs across the continuum of care in various settings. Expertise includes operations planning and management, start-up and multi-site operations, strategic partnerships, marketing leadership, regulatory compliance and financial management.

José Javier Otero, MD, PhD
Assistant Professor of Pathology, The Ohio State University

Scientific Interests:
General Mission:
The mission of the experimental neuropathology laboratory is to seek fundamental understanding of the mechanisms of diseases affecting the central and peripheral nervous systems.  My particular focus is in the understanding of developmental and neoplastic disorders of the CNS.

Project Focus:
The problem:
A major goal of this laboratory is to elucidate the etiologies of perinatal breathing disorders such as apnea of prematurity, CCHS, and, ultimately, the Sudden Infant Death Syndrome (SIDS).  SIDS is a tragic disorder affecting 1 in 2000 infants.  It is the second most common cause of infant death in the U.S., and although its incidence has decreased since adopting the “back to sleep” campaign, our epidemic of prematurity (which increases SIDS risk) threatens to increase the incidence of this disease.

Our Goal:
A goal of the laboratory is to develop a diagnostic screen that would be able to identify children at risk of perinatal breathing disorders such as apnea of prematurity or SIDS, and to triage their treatments most effectively.

Our Approach:
We propose to use induced pluripotent stem cells to model development of human breathing neurons. This “disease in a dish” model will help us understand how these neurons develop and can give us a tool to study genetic causes of apnea such as CCHS.  Additional approaches include next-gen sequencing and animal modeling (i.e., transgenic mouse technology) of these disorders. 


Posted on 16-Mar-12 by Geier, Eric
Tags: OSU Regenerative Medicine News
Trackback Url  |  Link to this post | Bookmark this post with: